NSAIDs and Chemoprevention

Current Cancer Drug Targets

Volumn 4, Issue 1, 2004, Pages 29-42

  Rao, Chinthalapally V ^a   Reddy, Bandaru S ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; INDOMETACIN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; VALDECOXIB;

ADENOMATOUS POLYP; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; LUNG CANCER; MORBIDITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 1542409978     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043481632     Document Type: Review

References (154)

1. World Health Organization. World Cancer Report 2003, Iarc Press, Lyon, France. 2003.
2. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M.J. Cancer Statistics, Ca Cancer J. Clin. 2003, 53, 5-26.
3. Wynder, E. L.; Kajitani, T.; Ishikawa, S.; Dodo, H.; Takano, A. Environmental Factors of Cancer of the Colon and Rectum. II. Japanese Epidemiological Data. Cancer 1969, 23, 1210-1200.
4. Wattenberg, L. W. Chemoprevention of Cancer. Cancer Res. 1985, 45, 1-8.
5. Kelloff, G. J. Perspectives on Cancer Chemoprevention Research and Drug Development. Adv. Cancer Res. 2000, 78, 1999-334.
6. Thun, M. J.; Namboodiri, M. M.; Heath, C. J. Jr. Aspirin Use and Reduced Risk of Fatal Colon Cancer. N. Engl. J. Med. 1991, 325, 1593-1596.
7. Thun, M. J.; Namboodiri, M. M.; Calle, E. E.; Flanders, W. D.; Heath, C. W. Jr. Aspirin Use and Risk of Fatal Cancer. Cancer Res. 1993, 53, 1322-1327.
8. Schreinemachers, D. M.; Everson, R. B. Aspirin Use and Lung, Colon, and Breast Cancer Incidence in A Prospective Study. Epidemiology 1994, 5, 138-146
9. Giovannucci, E.; Rimm, E. B.; Stampfer, M.; Colditz, G.; Asherio, A.; Willett, W. Aspirin Use and the Risk For Colorectal Cancer and Adenoma in Male Health Professionals. Ann. Intern. Med. 1994, 121, 241-246.
10. Giovannucci, E.; Willett, W. Dietary Factors and Risk of Colon Cancer. Ann. Intern. Med. 1994, 26, 443-52.
11. Collet, J. P.; Sharpe, C.; Belzile, E.; Boivin, J. F.; Hanley, J.; Abenhaim, L. Colorectal Cancer Prevention By Non-Steroidal Anti-Inflammatory Drugs: Effects of Dosage and Timing. Br. J. Cancer 1999, 81, 62-68.
12. Langman, M. J.; Cheng, K. K.; Gilman, E. A.; Lancashire, R. J. Effect of Anti-Inflammatory Drugs on Overall Risk of Common Cancer: Case-Control Study in General Practice Research Database. Br. Med. J. 2000, 320, 1642-1646.
13. Muscat, J.; Stellman, S. D.; Wynder, E. L. Nonsteroidal Antiinflammatory Drugs and Colorectal Cancer. Cancer 1994, 74, 1847-1854.
14. Greenberg, E. R.; Baron, J. A.; Freeman, D. H. Jr; Mandel, J. S.; Flaile, R. Reduced Risk of Large-Bowel Adenomas Among Aspirin Users. The Polyp Prevention Study Group. J. Natl. Cancer Inst. 1993, 85, 912-916.
15. Peleg, I. I.; Lubin, M. F.; Cotsonis, G. A.; Clark, W. S.; Wilcox, C. M. Long-Term Use of Nonsteroidal Antiinflammatory Drugs and Other Chemopreventors and Risk of Subsequent Colorectal Neoplasia. Dig. Dis. Sci. 1996, 41, 1319-1326.
16. Paganini-Hill, A.; Chao, A.; Ross, R.; Henderson, B. Aspirin Use and Chronic Diseases: A Cohort Study of the Elderly. Br. Med. J. 1989, 299, 1247-1250.
17. Kune, G.; Kune, S.; Watson, L. F. Colorectal Cancer Risk, Chronic Illnesses, Operations, and Medications: Case Control Results From the Melbourne Colorectal Cancer Study. Cancer Res. 1988, 48, 4399-4404.
18. Muller, A.; Sonnenberg, A.; Wasserman, I. H. Diseases Preceding Colon Cancer: A Case-Control Study Among Veterans. Dig. Dis. Sci. 1994, 39, 2480-1484.
19. Reeves, M. J.; Newcomb, P. A.; Trentham-Diez, A.; Storer, B. E.; Remington, P. Nonsteroidal Anti-Inflammatory Drug Use and Protection Against Colorectal Cancer in Women. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 955-960.
20. Logan, R. F.; Little, J.; Hawlin, P. G.; Hardcastle, J. D. Effect of Aspirin and Non-Steroidal Anti-Inflammatory Drugs on Colorectal Adenomas: Case-Control Study of Subjects Participating in the Nottingham Faecal Occult Blood Screening Programme. Br. Med. J. 1993, 307, 285-289.
21. Friedman, G. D.; Ury, K. Initial Screening For Carcinogenicity of Commonly Used Drugs. J. Natl. Cancer Inst. 1980, 65, 723-733.
22. Egan, K. M.; Stampfer, M. J.; Giovannucci, E.; Rosner, B. A.; Colditz, G. A. Prospective Study of Regular Aspirin Use and the Risk of Breast Cancer. J. Natl. Cancer Inst. 1996, 88, 988-993.
23. Harris, R. E.; Kasbari, S.; Farrar, W. B. Prospective Study of Nonsteroidal Anti-Inflammatory Drugs and Breast Cancer. Oncol. Rep. 1999, 6, 71-73.
24. Khuder, S. A.; Mutgi, A. B. Breast Cancer and Nsaid Use: A Meta-Analysis. Br. J. Cancer 2001, 84, 1188-1192.
25. Muscat, J. E.; Chen, S-Q.; Richie, J. P.; Altorki, N. K.; Citron, M.; Olson, S.; Neugut, A.I.; Stellman, S. D. Risk of Lung Carcinoma Among Users of Nonsteroidal Antiinflammatory Drugs. Cancer 2003, 97, 1732-1736.
26. Norrish, A. E.; Jackson, R. T.; Mcrae, C. U. Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Progression. Int. J. Cancer 1998, 77, 511-515.
27. Cramer, D. W.; Harlow, B.; Titus-Ernstoff, L.; Bohlke, K.; Welch, W. R.; Greenberg, E. R. Over-The-Counter Analgesics and Risk of Ovarian Cancer. Lancet 1998, 351, 104-107.
28. Tavani, A.; Gallus, S.; La Vecchia, C.; Conti, E.; Montella, M.; Francheschi, S. Aspirin and Ovarian Cancer: An Italian Case-Control Study. Ann. Oncol. 2000, 11, 1171-3117.
29. Labayle, D.; Fischer, D.; Vielh, P.; Drouhin, F.; Pariente, A.; Bories, C.; Duhamel, O.; Trousset, M.; Attali, P. Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis. Gastroenterology 1991, 101, 635-639.
30. Giardiello, F. M.; Hamilton, S. P.; Krush, A. J.; Piantadosi, S.; Hylind, L. M.; Celano, P.; Booker, S. V.; Robinson, C. R.; Offerhaus, G. J. Treatment of Colonic and Rectal Adenomas With Sulindac in Familial Adenomatous Polyposis. N. Engl. J. Med. 1993, 328, 1313-1316.
31. Steinbach, G.; Lynch, P. M.; Phillips, R. K.; Wallace, M. H.; Hawk E.; Gordon G. B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L. K.; Levin, B. The Effect of Celecoxib, A Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.
32. Giardiello, F. M. Nsaid-Induced Polyp Regression in Familial Adenomatous Polyposis Patients. Gastroenterol. Clin. North Am. 1996, 25, 349-362.
33. Lynch, H. T.; Thorson, A. G.; Smyrk, T. Rectal Cancer after Prolonged Sulindac Chemoprevention. A Case Report. Cancer 1995, 75, 936-938.
34. Tonelli, F.; Valanzano, R. Sulindac in Familial Adenomatous Polyposis [Letter]. Lancet 1993, 342, 1120.
35. Ladenheim, J.; Garcia, G.; Titzer, D.; Herzenberg, H.; Lavori, P.; Edson, R.; Omary, M. B. Effect of Sulindac on Sporadic Colonic Polyps. Gastroenterology 1995, 108, 1083-1087.
36. Bennett, A.; Del Tacca, M. Proceedings: Prostaglandins in Human Colonic Carcinoma. Gut 1975, 16, 409.
37. Jaffe, B. M. Prostaglandins and Cancer: An Update. Prostaglandins 1974, 6, 453-461.
38. Reddy, B. S.; Nayini, J.; Tokumo, K.; Rigottgy, K.; Zang, E.; Kelloff, G. Chemoprevention of Colon Carcinogenesis By Concurrent Administration of Piroxicam, A Nonsteroidal Antiinflammatory Drug with D,L-α -Difluromethylornithine, An Ornithine Decarboxylase Inhibitor, in Diet. Cancer Res. 1990, 50, 2562-2568.
39. Rao, C. V.; Tokumo, K.; Rigotty, J.; Zang, E.; Kelloff, G.; Reddy, B. S. Chemoprevention of Colon Carcinogenesis by Dietary Administration of Piroxicam α-Difluoromethylornithine, 16-α-Fluoro-5-Androsten-17-One, and Ellagic Acid Individually and in Combination. Cancer Res. 1991, 51. 4528-4534.
40. Rao, C. V.; Rivenson, A.; Simi, B.; Zang, E.; Kelloff, G.; Steele, V.; Recdy, B. S. Chemoprevention of Colon Carcinogenesis By Sulindac, A Nonsteroidal Anti-Inflammatory Agent. Cancer Res. 1995, 55, 1464-1472.
41. Pollard M.; Zedeck M.S. Induction of Colon Tumors in 1,2-Dimethylhydrazine-Resistant Lobund Wistar Rats By Methylazoxymethanol Acetate. J. Natl. Cancer Inst. 1978, 61, 493-494.
42. Pollard, M.; Luckert, P. H. Indomethacin Treatment of Rats With Dimethylhydrazine-Induced Intestinal Tumors. Cancer Treat. Rep. 1980, 64,1323-1327.
43. Pollard, M.; Luckert, P. H. Effect of Indomethacin on Intestinal Tumors Induced in Rats By the Acetate Derivative of Dimethylnitrosoamine. Science. 1981, 214, 558-559.
44. Pollard, M.; Luckert, P. H. Prolonged Antitumor Effect of Indomethacin on Autochthonous Intestinal Tumors in Rats. J. Natl. Cancer Inst. 1983, 70, 1103-1105.
45. Pollard, M.; Luckert, P.H.; Schmidt, M.A. The Suppressive Effect of Piroxicam on Autochthonous Intestinal Tumors in the Rat. Cancer Lett. 1983, 21, 57-61.
46. Pollard, M.; Luckert, P. H. Prevention and Treatment of Primary Intestinal Tumors in Rats by Piroxicam. Cancer Res. 1989, 49, 6471-6473.
47. Narisawa, T.; Sato, M.; Tani, M.; Takahashi, T.; Goto, A. Inhibition of Development of Methylnitrosourea-Induced Rat Colon Tumors By Indomethacin Treatment. Cancer Res. 1981, 41, 1954-1957.
48. Narisawa, T.; Sato, M.; Sano, M.; Takahashi, T. Inhibition of Development of Methylnitrosourea-Induced Rat Colonic Tumors By Peroral Administration of Indomethacin. Gann. 1982, 73, 377-381.
49. Narisawa, T.; Satoh, M.; Sano, M.; Takahashi, T. Inhibition of Initiation and Promotion by N-Methylnitrosourea-Induced Colon Carcinogenesis in Rats by Non-Steroid Anti-Inflammatory Agent Indomethacin. Carcinogenesis 1983, 4, 1225-1227.
50. Nigro, N. D.; Bull, A. W.; Boyd, M. E. Inhibition of Intestinal Carcinogenesis in Rats: Effect of Difluoromethylornithine With Piroxicam Or Fish Oil. J. Natl. Cancer Inst. 1986, 77, 1309-1313,
51. Reddy, B. S.; Maruyama, H.; Kelloff, G. Dose-Related Inhibition of Colon Carcinogenesis By Dietary Piroxicam, A Nonsteroidal Antiinflammatory Drug, During Different Stages of Rat Colon Tumor Development. Cancer Res. 1987, 47, 5340-5346.
52. Reddy, B. S.; Tokumo, K.; Kulkarni, N.; Aliga, C.; Rao, C. V.; Kelloff, G. Inhibition of Colon Carcinogenesis By Prostaglandin Synthesis Inhibitors and Related Compounds. Carcinogenesis 1992, 13, 1019-1023.
53. Reddy, B.S.; Rao, C.V.; Rivenson, A.; Kelloff, G. Inhibitory Effect of Aspirin on Azoxymethane-Induced Colon Carcinogenesis in F344 Rats. Carcinogenesis 1993, 14, 1493-1497.
54. Moorghen, M.; Ince, P.; Finney, K. J.; Sunter, J. P.; Watson, A. J.; Appleton, D. R. The Effect of Sulindae on Colonic Tumor Formation in Dimethylhydrazine-Treated Mice. Acta. Histochem. Suppl. 1990, 39, 195-199.
55. Skinner, S. A.; Penney, A. G.; O'brien, P. Sulindac Inhibits the Rate of Growth and Appearance of Colon Tumors in the Rat. Arch. Surg. 1991, 126, 1094-1096.
56. Kawamori, T.; Rao, C. V.; Seibert, K.; Reddy, B. S. Chemopreventive Activity of Celecoxib, A Specific Cyclooxygenase-2 Inhibitor, Against Colon Carcinogenesis. Cancer Res. 1998, 58, 409-412.
57. Reddy, B. S.; Kawamori, T.; Lubet, R. A.; Steele, V. E.; Kelloff, G. J.; Rao, C. V. Chemopreventive Efficacy of Sulindac Sulfone Against Colon Cancer Depends on Time of Administration During Carcinogenic Process. Cancer Res. 1999, 59, 3387-3391.
58. Wargovich, M. J.; Chen, C. D.; Harris, C.; Yang, E.; Velasco, M. Inhibition of Aberrant Crypt Growth by Non-Steroidal Anti-Inflammatory Agents and Differentiation Agents in the Rat Colon. Int. J. Cancer 1995, 60, 515-519.
59. Reddy, B. S.; Rao, C. V.; Seibert, K. Evaluation of Cyclooxygenase-2 Inhibitor For Potential Chemopreventative Properties in Colon Carcinogenesis. Cancer Res. 1996, 56, 4566-4569.
60. Takahashi, M.; Fukutake, M.; Yokota, S.; Ishida, K.; Wakabayashi, K.; Sugimura, T. Suppression of Azoxymethane-Induced Aberrant Crypt Foci in Rat Colon by Nimesulide, A Selective Inhibitor of Cyclooxygenase 2. J. Cancer Res. Clin. Oncol. 1996, 122, 219-222.
61. Reddy, B. S.; Hirose, Y.; Lubet, R.; Steele, V.; Kelloff, G.; Paulson, S.; Rao, C. V. Chemoprevention of Colon Cancer By Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered During Different Stages of Carcinogenesis. Cancer Res. 2000, 60, 293-297.
62. Weisburger, J.; Reddy, B.; Joftes, D. Colorectal Cancer. International Union Against Cancer (Uicc) Technical Report 19. Geneva (Switzerland): Uicc; 1975.
63. International Agency for Research on Cancer (IARC). Non-Steroidal Anti-Inflammatory Drugs. In: Iarc Handbooks of Cancer Prevention. Lyon (France): IARC Press; 1997.
64. Reddy, B. S.; Rao, C. V. Novel Approaches For Colon Cancer Prevention By Cyclooxygcnase Inhibitors. J. Env. Pathol. Toxicol. Oncol. 2002, 21, 155-164.
65. Botha, J. H.; Robinson, K. M.; Ramchurren, N.; Reddi, K.; Norman, R. J. Human Esophageal Carcinoma Cell Lines: Prostaglandin Production, Biological Properties, and Behavior in Nude Mice. J. Natl. Cancer Inst. 1986, 76, 1053-1056.
66. Li, M.; Lotan, R.; Levin, B.; Tahara, E.; Lippman, S. M.; Xu, X. C. Aspirin Induction of Apoptosis in Esophageal Cancer: A Potential For Chemoprevention. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 545-549.
67. 2 on Gastrointestinal Tumorigenesis Induced By N-Methyl-N′-Nitro-N-Nitrosoguanidine in Rats. I. Squamous Epithelium and Mesenchymal Tissue. J. Natl. Cancer Inst. 1987, 78, 923-929.
68. Shibata, M. A.; Hirose, M.; Masuda, A.; Kato T.; Mutai, M.; Ito, N. Modification of Bha Forestomach Carcinogenesis in Rats: Inhibition By Diethylmaleate Or Indomethacin and Enhancement By A Retinoid. Carcinogenesis 1993, 14, 1265-269.
69. Fischer, S. M.; Lo, H. H.; Gordon, G. B.; Seibert, K.; Kelloff, G.; Lubet, R. A.; Conti, C.J. Chemopreventive Activity of Celecoxib, A Specific Cyclooxygenase-2 Inhibitor, and Indomethacin Against Ultraviolet Light-Induced Skin Carcinogenesis. Mol. Carcinog. 1999, 25, 231-240.
70. Rozic, J. G.; Chakraborty, C.; Lala, P. K. Cyclooxygenase Inhibitors Retard Murine Mammary Tumor Progression by Reducing Tumor Cell Migration, Invasiveness and Angiogenesis. Int. J. Cancer 2001, 93, 497-506.
71. Liu, C.H.; Chang, S. H.; Narko, K.; Trifan, O. C.; Wu, M. T.; Smith, E.; Haudenschild, C.; Lane, T.F.; Hla, T. Overexpression of Cyclooxygenase-2 Is Sufficient To Induce Tumorigenesis in Transgenic Mice. J. Biol. Chem. 2001, 276, 18563-18569.
72. Alshafie, G. A.; Abou-Issa, H. M.; Seibert, K.; Harris, R. E. Chemotherapeutic Evaluation of Celecoxib, A Cyclooxygenase-2 Inhibitor, in A Rat Mammary Tumor Model. Oncol. Rep. 2000, 7, 1377-1381.
73. Nakatsugi, S.; Ohla, T.; Kawamori, T.; Mutoh, M.; Tanigawa, T.; Watanabe, K.; Sugie, S.; Sugimura, T.; Wakabayashi, K. Chemoprevention By Nimesulide, A Selective Cyclooxygenase-2 Inhibitor, of 2-Amino-1-Methyl-6-Phenylimidazo[4,5-B]Pyridine (Phip)-Induced Mammary Gland Carcinogenesis in Rats. Jpn. J. Cancer Res. 2000, 91, 886-1892.
74. Yao, R.; Rioux, N.; Castonguay, A.; You, M. Inhibition of Cox-2 and Induction of A Apoptosis: Two Determinants of Nonsteroidal and Anti-Inflammatory Drugs' Chemopreventive Efficacies in Mouse Lung Tumorigenesis. Exp. Lung Res. 2000, 26, 731-742.
75. Tsubouchi, Y.; Mukai, S.; Kawahito, Y.; Yamada, R.; Kohno, M.; Inoue, K. ; Sano, H. Meloxicam Inhibits the Growth of Non-Small Cell Lung Cancer. Anti Cancer Res. 2000, 20, 2867-2872.
76. Duperron, C.; Castonguay, A. Chemoprcvention Efficacies of Aspirin and Sulindac Against Lung Tumorigenesis in A/J Mice. Carcinogenesis 1997, 18, 1001-1006.
77. Rioux, N.; Castonguay, A. Prevention of NNK-Induced Lung Tumorigenesis in A/J Mice by Acetylsalicylic Acid and NS-398. Cancer Res. 1998, 58, 5354-5360.
78. Tremblay, C.; Dore, M.; Bochsler, P.; Sirois, J. Induction of Prostaglandin G/H Synthase-2 in A Canine Model of Spontaneous Prostatic Adenocarcinoma. J. Natl. Cancer Inst. 1999, 91, 1398-1403.
79. Liu, X. H.; Kirschenbaum, A.; Yao, S.; Lee, R.; Holland, J. F.; Levine, A. C. Inhibition of Cyclooxygenase-2 Suppresses Angiogenesis and the Growth of Prostate Cancer in Vivo. J. Urol. 2000, 164, 820-825.
80. Okajima, A.; Denda, A.; Ozono, S.; Takahama, M.; Akai, H.; Sasaki, Y.; Kitayama, W.; Wakabaysghi, K.; Konishi, Y. Chemopreventive Effects of Nimesulide, A Selective Cyclooxygenase-2 Inhibitor, on the Development of Rat Urinary Bladder Carcinomas Initiated By N-Butyl-N-(4-Hydroxybutyl)Nitrosamine. Cancer Res. 1998, 58, 3028-3031.
81. Grubbs, C. J.; Lubct R. A.; Koki, A. T.; Leahy, K. M.; Masfcrrer, J. L.; Steele, V. E.; Kelloff, G. J.; Hill, D. L.; Seibert, K. Celecoxib Inhibits N-Butyl-N-(4-Hydroxybutyl)-Nitrosamine-Induced Urinary Bladder Cancers in Male B6d2f1 Mice and Female Fischer-344 Rats. Cancer Res. 2000, 60, 5599-5602.
82. Klan, R.; Knispel, H.; Meier, T. Acetylsalicylic Acid Inhibition of N-Butyl-(4-Hydroxybutyl)Nitrosamine-Induced Bladder Carcinogenesis in Rats. J. Cancer Res. Clin. Oncol. 1993, 119, 482-485.
83. Jacoby, R. F.; Scibert, K.; Cole, C. E.; Kelloff, G.; Lubet, R. A. the Cyclooxygenase-2 Inhibitor Celecoxib Is A Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis. Cancer Res. 2000, 60, 5040-5044.
84. Boolbol, S. K.; Dannenberg, A. J.; Chadburn, A.; Martucci, C.; Guo, X. J.; Ramonetti, J. T.; Abreugoris, M.; Newmark, H.L.; Lipkin, M.L.; DeCosse, J.J.; Bertagolli, M.M. Cyclooxygenase-2 Overexpression and Tumor Formation Are Blocked By Sulindac in A Murine Model of Familial Adenomatous Polyposis. Cancer Res. 1996, 56, 2556-2560.
85. Chiu, C. H.; Mcentee, M. F.; Whelan, J. Sulindac Causes Rapid Regression of Preexisting Tumors in Min/+ Mice Independent of Prostaglandin Biosynthesis. Cancer Res. 1997, 57, 4267-4273.
86. Mahmoud, N. N.; Bilinski, R. T.; Churchill, M. R.; Edelmann W.; Kucherlapati R.; Bertagnolli, M. M. Genotype-Phenotype Correlation in Murine Apc Mutation: Differences in Enterocyte Migration and Response To Sulindac. Cancer Res. 1999, 59, 353-359.
87. Mahmoud, N. N.; Dannenberg, A. J.; Mestre, J.; Bilinski, R. T.; Churchill, M. R.; Martucci, C.; Newmark, H.; Bertagnolli, M.M. Aspirin Prevents Tumors in A Murine Model of Familial Adenomatous Polyposis. Surgery 1998, 124, 225-231.
88. (Delta)716 Mouse By Rofecoxib, A Specific Cyclooxygenase-2 Inhibitor. Cancer Res. 2001, 61, 1733-1740.
89. Marnett, L. J. Aspirin and the Potential Role of Prostaglandins in Colon Cancer. Cancer Res. 1992, 52, 5575-5589.
90. Smith, W. L.; Dewitt, D. L.; Garavito, R. M. Cyclooxygenases: Structural, Cellular, and Molecular Biology. Annu. Rev. Biochem. 2000, 69, 145-182.
91. Eberhart, C. E.; Dubois, R. N. Eicosanoids and the Gastrointestinal Tract. Gastroenterology 1995, 109, 285-301.
92. Kargman, S. L.; O'neill, G. P.; Vickers, P. J.; Evans, J. F.; Mancini, J. A.; Jothy, S. Expression of Prostaglandin G/H Synthase-1 And -2 Protein in Human Colon Cancer. Cancer Res. 1995, 55, 2556-2559.
93. Dubois, R. N.; Radhika, A.; Reddy, B. S.; Entingh, A. J. Increased Cyclooxygenase-2 Levels in Carcinogen-Induced Rat Colonic Tumors. Gastroenterology 1996, 110, 1259-1262.
94. Taketo, M. M. Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I) J. Natl. Cancer Inst. 1998, 90, 1529-1536.
95. Tsujii, M.; Dubois, R. N. Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase-2. Cell 1995, 83, 493-501.
96. Morrow, J. D.; Roberts, L. J. Lipid-Derived Autacoids. In: Hardman Jg, Limbird Le, Editors. the Pharmacological Basis of Therapeutics. New York (Ny): Mcgraw-Hill; 2001. P. 669-685.
97. Patrignani, P.; Filabozzi, P.; Patrono, C. Selective Cumulative Inhibition of Platelet Thromboxane Production By Low-Dose Aspirin in Healthy Subjects. J. Clin. Invest. 1982, 69, 1366-1372.
98. nd; Lawson J.A.; Brash, A.R. Endogenous Biosynthesis of Prostacyclin and Thromboxane and Platelet Function During Chronic Administration of Aspirin in Man. J. Clin. Invest. 1983, 71, 678-688.
99. Peterson, W. L.; Cryer, B. Cox-1-Sparing Nsaids - Is the Enthusiasm Justified? J. Am. Med. Assoc. 1999, 282, 1961-1963.
100. Willoughby, D. A.; Moore, A. R.; Colville-Nash, P. R. Cox-1, Cox-2, and Cox-3 and the Future Treatment of Chronic Inflammatory Disease. Lancet 2000, 355, 646-648.
101. Langenbach, R.; Morham, S. G.; Tiano, H. F.; Loftin, C. D.; Ghanayem B. I.; Chulada, P.C.; Mahler, J.F.; Lee, C.A.; Goulding, E.H.; Kluckman, K.D.; Kim, H.S.; Smithies, O. Prostaglandin Synthase-1 Gene Disruption in Mice Reduces Arachidonic Acid-Induced Inflammation and Indomethacin-Induced Gastric Ulceration. Cell 1995, 83, 483-492.
102. Langenbach, R.; Loftin, C.; Lee, C.; Tiano, H. Cyclooxygenase Knockout Mice: Models For Elucidating Isoform-Specific Functions. Biochem. Pharmacol. 1999, 58, 1237-4126.
103. Patrono, C.; Patrignani, P.; Garcia Rodriguez, L. A. Cyclooxygenase-Selective Inhibition of Prostanoid Formation: Transducing Biochemical Selectivity Into Clinical Read-Outs. J. Clin. Invest. 2001, 108, 7-13.
104. Giovannucci, E.; Egan, K. M.; Hunter, D. J.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Speizer, F.E. Aspirin and the Risk of Colorectal Cancer in Women. N. Engl. J. Med. 1995, 333, 609-614.
105. He, T. C.; Chan, T. A.; Vogelstein, B.; Kinzler, K. W. PPARdelta Is an Apc-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs. Cell 1999, 99, 335-345.
106. Afford, S.; Randhawa, S. Apoptosis. Mol. Pathol. 2000, 53, 55-63.
107. Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Apoptosis and Apc in Colorectal Tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7950-7954.
108. Kinzler, K. W.; Vogelstein, B. Colorectal Tumors. In: The Genetic Basis of Human Cancer. Vogelstein, B.; Kinzler K., Eds. New York, NY: Mcgraw-Hill; 1998. pp. 565-587.
109. Bedi, A.; Pasricha, P. J.; Akhtar, A. J.; Barber, J. P.; Bedi, G. C.; Giardiello F. M.; Zehnbauer, B. A.; Hamilton, S. R.; Jones, R. J. Inhibition of Apoptosis During Development of Colorectal Cancer. Cancer Res. 1995, 55, 1811-1816.
110. Pasricha, P. J.; Bedi, A.; O'connor K.; Rashid, A.; Akhtar, A. J.; Zahurak, M. V.; Piantadosi, S.; Hamilton, S.R.; Giardiello, F.M. The Effects of Sulindac on Colorectal Proliferation and Apoptosis in Familial Adenomatous Polyposis. Gastroenterology 1995, 109, 994-998.
111. Samaha, H.; Kelloff, G.; Steele, V.; Rao, C.; Reddy, B. S. Modulation of Apoptosis By Sulindac, Curcumin, Phenylethyl-3-Methylcaffeate, and 6-Phenylhexyl Isothiocyanate: Apoptotic Index As A Biomarker in Colon Cancer Chemoprevention and Promotion. Cancer Res. 1997, 57, 1301-1305.
112. Uefuji, K.; Ichikura, T.; Shinomiya, N.; Mochizuki, H. Induction of Apoptosis by Jte-522, A Specific Cyclooxygenase-2 Inhibitor, in Human Gastric Cancer Cell Lines. Anti Cancer Res. 2000, 20, 4279-4284.
113. Souza, R. F.; Shewmake, K.; Beer, D. G.; Cryer, B.; Spechler, S. J. Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells. Cancer Res. 2000, 60, 5767-5772.
114. 2 Production. J. Oral Pathol. Med. 2001, 30, 41-47.
115. Joki, T.; Heese, O.; Nikas, D. C.; Bello, L.; Zhang, J.; Kraeft, S. K.; Seyfried, N.T.; Abe, T.; Chen, L.B.; Carroll, R.S.; Black, P.M. Expression of Cyclooxygenase 2 (COX-2) in Human Glioma and in Vitro Inhibition By A Specific COX-2 Inhibitor, Ns-398. Cancer Res. 2000, 60, 4926-4931.
116. Molina, M. A.; Sitja-Arnau, M.; Lemoine, M. G.; Frazier, M. L.; Sinicrope, F. A. Increased Cyclooxygenase-2 Expression in Human Pancreatic Carcinomas and Cell Lines: Growth Inhibition By Nonsteroidal Anti-Inflammatory Drugs. Cancer Res. 1999, 59, 4356-4362.
117. Marx, J. Cancer Research. Anti-Inflammatories Inhibit Cancer Growth - But How? [News] Science 2001, 291, 581-582.
118. I Delay in Cells Overexpressing Prostaglandin Endoperoxide Synthase-2. Cancer Res. 1996, 56, 733-737.
119. Elder, D. J.; Halton, D. E.; Hague, A.; Paraskeva, C. Induction of Apoptotic Cell Death in Human Colorectal Carcinoma Cell Lines By A Cyclooxygenase-2 (Cox-2)-Selective Nonsteroidal Anti-Inflammatory Drug: Independence From Cox-2 Protein. Clin. Cancer Res. 1997, 3, 1679-1683.
120. Shiff, S.J.; Koutsos, M.I.; Qiao, L.; Rigas, B. Nonsteroidal Antiinflammatory Drugs Inhibit the Proliferation of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis. Exp. Cell Res. 1996, 222, 179-188.
121. Malisetty, V. S.; Herzog, C.; Rao, C. V. Celecoxib Inhibition of COX-2 in Colon Cancer Cell Lines Increases the Nuclear Localization of Active P53. Cancer Res. 2003, 63, 5239-5242.
122. Vane, J. R. Inhibition of Prostaglandin Synthesis As A Mechanism of Action For Aspirin-Like Drugs. Nat. New Biol. 1971, 231, 232-235.
123. Cao, Y.; Pearman, A. T.; Zimmerman, G. A.; Mcintyre, T. M.; Prescott, S. M. Intracellular Unesterified Arachidonic Acid Signals Apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 11280-11285.
124. Chan, T. A.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Mechanisms Underlying Nonsteroidal Antiinflammatory Drug-Mediated Apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 681-686.
125. He, T. C.; Sparks, A. B.; Rago, C.; Hermeking, H.; Zawel, L.; Da Costa, I. T.; Morin, P.J.; Vogelstein, B.; Kinzlcr, K.W. Identification of C-Myc As A Target of the APC Pathway. Science 1998, 281, 1509-1512.
126. Rice, P. L.; Goldberg, R. J.; Ray, E. C.; Driggers, L. J.; Ahnen, D. J. Inhibition of Extracellular Signal-Regulated Kinase 1/2 Phosphorylation and Induction of Apoptosis by Sulindae Metabolites. Cancer Res. 2001, 61, 1541-1547.
127. Yamamoto, Y.; Yin, M. J.; Lin, K. M.; Gaynor, R. B. Sulindac Inhibits Activation of the Nf-Kappab Pathway. J. Biol. Chem. 1999, 274, 27307-27314.
128. Schwenger, P.; Bellosta, P.; Victor, I.; Basilico, C.; Skolnik, E. Y.; Vilcek, J. Sodium Salicylate Induces Apoptosis Via P38 Mitogen-Activated Protein Kinase But Inhibits Tumor Necrosis Factor-Induced C-Jun N-Terminal Kinase/Stress-Activated Protein Kinase Activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2869-7283.
129. Wu, G. D. A Nuclear Receptor to Prevent Colon Cancer. N. Engl. J. Med. 2000, 342, 651-653.
130. Shureiqi, I.; Chen, D.; Lotan, R.; Yang, P.; Newman, R. A.; Fischer, S. M.; Lippman, S.M. 15-Lipoxygenase-1 Mediates Nonsteroidal Anti-Inflammatory Drug-Induced Apoptosis Independently of Cyclooxygenase-2 in Colon Cancer Cells. Cancer Res. 2000, 60, 6846-6850.
131. Jones, M. K.; Wang, H.; Peskar, B. M.; Levin, E.; Itani, R. M.; Sarfeh, I. J.; Tarnawski, A.S. Inhibition of Angiogenesis By Nonsteroidal Anti-Inflammatory Drugs: Insight Into Mechanisms and Implications For Cancer Growth and Ulcer Healing. Nat. Med. 1999, 5, 1418-1423.
132. Masferrer, J. L.; Leahy, K. M.; Koki, A.T.; Zweifel, B.S.; Settle, S.L.; Woerner, B.M.; Edwards, D.A.; Flickinger, A.G.; Moore, R.J.; Seibert, K. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Res. 2000, 60, 1306-1311.
133. Williams, C. S.; Tsujii, M.; Reese, J.; Dey, S. K.; Dubois, R. N. Host Cyclooxygenase-2 Modulates Carcinoma Growth. J. Clin. Invest. 2000, 105, 1589-1594.
134. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; Dubois R. N. Cyclooxygenase Regulates Angiogenesis Induced By Colon Cancer Cells. Cell 1998, 93, 705-716.
135. Langman, M. J.; Jensen, D. M.; Watson, D. J.; Harper, S. E.; Zhao, P. L. ; Quan, H.; Bolognese, J. A.; Simon, T. J. Adverse Upper Gastrointestinal Effects of Rofecoxib Compared With Nsaids. J. Am. Med. Assoc. 1999, 282, 1929-1933.
136. Williams, J. L.; Borgo, S.; Hasan, I.; Castillo, E.; Traganos, F.; Rigas, B. Nitric-Oxide Releasing Nsaids Alter the Kinetics of Human Colon Cancer Cell Lines More Effectively Than Traditional Nsaids: Implications for Colon Cancer Prevention. Cancer Res. 2001, 61, 3285-3289.
137. Rao, C. V.; Rivenson, A.; Simi, B.; Reddy, B. S. Chemoprevention of Colon Carcinogenesis By Dietary Curcumin, A Naturally Occurring Plant Phenolic Compound. Cancer Res. 1995, 55, 259-266.
138. Rao, C. V.; Desai, D.; Rivenson, A.; Simi, B.; Amin, S.; Reddy, B. S. Chemoprevention of Colon Carcinogenesis By Phenlethyl-3-Methylcaffeate. Cancer Res. 1995, 55, 2310-2315.
139. Kawamori, T.; Lubet, R.; Steele, V. E.; Kelloff, G. J.; Kaskey, R. B.; Rao, C. V.; Reddy, B. S. Chemopreventive Effect of Curcumin, A Naturally-Occurring Antiinflamatory Agent, During the Promotion/Progression Stages of Colon Cancer. Cancer Res. 1999, 59, 597-601.
140. Rao, C. V.; Simi, B.; Reddy, B. S. Inhibition By Dietary Curcumin of Azoxymethane-Induced Ornithine Decarboxylase, Tyrosine Protein Kinasc, Arachidonic Acid Metabolism and Aberrant Crypt Foci in the Rat Colon. Carcinogenesis 1993, 14, 2219-2225.
141. Rao, C. V.; Desai, D.; Simi, B.; Kulkarni, N.; Amin, S.; Reddy, B. S. Inhibitory Effects of Caffeic Acid Esters on Azoxymethane-Induced Biochemical Changes and Aberrant Crypt Foci Formation in Rat Colon. Cancer Res. 1993, 53, 4182-4188.
142. Huang, M. T.; Ma, W.; Yen, P.; Xie, J. G.; Han, J.; Frenkel, K.; Grunberger, D.; Conney, A. H. Inhibitory Effects of Caffeic Acid Phenethyl Ester (CAPE) on 12-O-Tetradecanoylphorbol-13-Acetate-Induced Tumor Promotion in Mouse Skin and the Synthesis of Dna, Rna and Protein in Hela Cells. Carcinogenesis 1996, 17, 761-765.
143. Mahmoud, N. N.; Carothers, A. M.; Grunberger, D.; Bilinski, R. T.; Churchill, M. R.; Martucci, C.; Newmark, H. L.; Bertagnolli, M. M. Plant Phenolics Decrease Intestinal Tumors in an Animal Model of Familial Adenomatous Polyposis. Carcinogenesis 2000, 21, 921-927.
144. Xu, Y. X.; Pindolia, K. R.; Janakiraman, N.; Chapman, N.; Gautam, S. C. Curcumin Inhibits 11-1α and TNF-α Induction of AP-1 and NF-κB Dna-Binding Activity in Bone Marrow Stromal Cells. Hematophathol. Mol. Hematol. 1998, 11, 49-62.
145. Taylor, J. D. Lipoxygenase Regulation of Membrane Expression of Tumor Cell Glycoproteins and Subsequent Metastasis. Adv. Prostaglandin Thromboxane Leukot. Res. 1989, 19, 439-443
146. Natarajan, K.; Singh, S.; Burke, T. R. Jr; Grunberger, D.; Aggarwal, 13. B. Caffeic Acid Phenethyl Ester is a Potent and Specific Inhibitor of Activation of Nuclear Transcription Factor Nf-Kappa B. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9090-9095.
147. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C.M. Ombinatorial Chemoprevention of Intestinal Neoplasia. Nat. Med. 2000, 6, 1024-1028.
148. Gupta, R. A.; Dubois, R. N. Combinations for Cancer Prevention. Nat. Med. 2000, 6, 974-5.
149. Agarwal, B.; Rao, C. V.; Bhendwal, S.; Ramey, W. R.; Shirin, H.; Reddy, B. S. Lovastatin Augments Sulindac-Induced Apoptosis in Colon Cancer Cells and Potentiates Chemopreventive Effect of Sulindac. Gastroenterology 1999, 117, 838-847.
150. Malisetty, V. S.; Cooma, I.; Reddy, B. S.; Rao, C. V. Lamin B, Caspase-3-Activity, and Apoptosis Induction By A Combination of Hmg-Coa Reductase Inhibitor and Cox-2 Inhibitors: A Novel Approach in Developing Effective Chemopreventive Regimens. Int. J. Oncol. 2002, 20, 753-759.
151. 2 Levels in Rat Colon. Carcinogenesis 1999, 20, 425-430.
152. Rao, C. V.; Hirose, Y.; Cooma, I.; Reddy, B. S. Modulation of Experimental Colon Tumorigenesis By Types and Amounts of Dietary Fatty Acids. Cancer Res. 2001, 61, 1927-1933.
153. Reddy, B. S.; Rao, C. V. Colon Cancer: A Role for Cyclooxygenase-2 Specific Nonsteriodal Anti-Inflammatory Drugs. Drugs Aging 2000, 6, 329-334.
154. Whelan, J.; Mcentee, M. F. Nonsteroidal Antiinflammatory Drugs. Prostaglandins, and Apc Driven Intestinal Tumorigenesis. In Cancer Drug Discovery and Development - COX-2 Blockade in Cancer Prevention and Therapy; Harris, R. E.; Ed, Humana, Press, New Jersy, 2003, pp. 117-145.